Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.
Fiche publication
Date publication
février 2018
Journal
The Lancet. Haematology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre, Pr DELMER Alain
Tous les auteurs :
Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V, ,
Lien Pubmed
Résumé
Most patients with chronic lymphocytic leukaemia relapse after initial therapy combining chemotherapy with rituximab. We assessed the efficacy and safety of rituximab maintenance treatment versus observation for elderly patients in remission after front-line abbreviated induction by fludarabine, cyclophosphamide, and rituximab (FCR).
Mots clés
Aged, Female, Humans, Immunotherapy, Leukemia, Lymphocytic, Chronic, B-Cell, drug therapy, Male, Rituximab, pharmacology
Référence
Lancet Haematol. 2018 Feb;5(2):e82-e94